Trial Profile

Phase I, Open Label, Single Dose Study to Determine the Pharmacokinetics, Metabolism, and Excretion of [14C]-Evobrutinib in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evobrutinib (Primary)
Indications Autoimmune disorders; Encephalomyelitis; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
Focus Pharmacokinetics
Sponsors Merck KGaA

Most Recent Events

25 Feb 2019 Status changed from recruiting to completed.
22 Nov 2018 Status changed from not yet recruiting to recruiting.
29 Oct 2018 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com